Merck

Edwards Lifesciences

Follow

Edwards Lifesciences (NYSE: EW) is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. For our legal terms and trademarks, please visit: http://bit.ly/2fv28iO

American Regent

Follow

American Regent has a long history. From small beginnings in 1967 as a US-based manufacturer, the company has grown to be one of the leading pharmaceutical companies in the United States. Our growing business is comprised of a mix of branded and generic injectables. For nearly 25 years, we have been the leader in IV iron therapy, supplying the market with the two top-selling brands in the US. For over 40 years, our animal health business has proudly delivered solutions that support the long-term health and well-being of horses and dogs, anchored by two of the leading animal joint health brands. Our legacy, spanning nearly 60 years, is built on an unwavering commitment to ensuring that the people and animals we serve have the essential medicines they need.

SCHOTT

Follow

When others say no, we say yes. Because at SCHOTT we believe that shared responsibility can release the energy to achieve the impossible. As a global material technology group, we are constantly exploring unique and innovative ways to make a difference for businesses and people. Being a foundation company, SCHOTT has anchored a responsibility for scientific research, society and the environment deeply in its DNA. Represented in over 33 countries by 17,200 employees, we are a highly skilled partner for many high-tech industries: Healthcare, Home Appliances & Living, Consumer Electronics, Semiconductors & Datacom, Optics, Industry & Energy, Automotive, Astronomy & Aerospace. Whatever challenges the future might hold, we can’t wait to come up with innovative solutions and turn visions into reality.

Regeneron

Follow

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to 12 medicines approved in the United States and/or other countries and numerous product candidates in development, nearly all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. We do not interview candidates on Google Hangouts. Any questions about job listings can be directed to candidatesupport@regeneron.com . We also do not hire for “at-home data entry” positions.

Lundbeck

Follow

Today, millions of people all over the world live with brain diseases. Every day, at Lundbeck we strive to further understand these diseases, develop the best therapies to treat them and make a difference to people living with them. We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization. Our purpose is clear: We are committed to advancing brain health and transforming lives Driven by research… For more than 70 years, we’ve been pushing the boundaries of neuroscience. By combining the logic of science with our passion for making a difference to patients, we’ve pioneered some of the most important and commonly used therapies within antipsychotics and antidepressants. We work closely with patients, healthcare professionals and the neuroscience community to uncover causes and to find new treatments that can bring back quality of life to people living with brain diseases. …raising our voice… When every other organ in our body gets sick, we find compassion and care. When our brain suffers, the world typically turns away. As a global specialist, we owe it to those who live with brain diseases to fight stigma and promote better treatment. That’s why we work to improve understanding and parity of care across communities and societies – so we can empower people and rebuild hope. …giving profit a purpose… The Lundbeck Foundation is the majority owner of Lundbeck. Foundation ownership allows us to stay focused on our areas of specialization. It also means that we are in a position to give back. With donations of approximately DKK 500 million a year to biomedical research, the foundation supports the progress of health science. …and working with one aim. Today, we’re over 5,000 people in +20 countries. We build on our Danish heritage, fostering a culture of collaboration and responsibility. Whether we work in labs or in the field, we all have the same aim: to develop innovative treatments that improve the lives of people living with brain diseases.

Daiichi Sankyo

Follow

Daiichi Sankyo, Inc. is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, pain management, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma.